Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain MDCO message board posts where the ticker symbol MDCO has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest MDCO SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-009496 Size: 4 KB
2018-07-05
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001341004-18-000343 (34 Act)  Size: 129 KB
2018-06-11 005-60201
18892102
8-K  Documents Current report, item 5.07
Acc-no: 0001113481-18-000036 (34 Act)  Size: 46 KB
2018-06-06 000-31191
18883901
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-007960 Size: 8 KB
2018-06-04
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-007959 Size: 7 KB
2018-06-04
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-007957 Size: 6 KB
2018-06-04
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-007956 Size: 6 KB
2018-06-04
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-007955 Size: 6 KB
2018-06-04
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-007954 Size: 6 KB
2018-06-04
SD  Documents Acc-no: 0001113481-18-000034 (34 Act)  Size: 23 KB 2018-05-30 000-31191
18868297
More MDCO SEC Filings


Related news from
Fri, 13 Jul 2018
04:01:41 +0000
[$$] High-profile health app under scrutiny after doctors’ complaints
An app that uses artificial intelligence to assess medical symptoms and boasts more than 2.5m users faces regulatory scrutiny after complaints from doctors, who warn it can miss signs of serious illness. The UK medicines regulator asked questions about the app after one doctor complained it had failed to identify symptoms of a heart attack or deep vein thrombosis. Some patients in London can register to use the app’s video consultations to communicate with a doctor instead of registering with a traditional GP’s surgery.
Wed, 11 Jul 2018
09:08:52 +0000
[$$] Supply of 100 UK medicines to be disrupted, warns EMA
The supply of more than 100 medicines manufactured solely in the UK is at risk of disruption post-Brexit because necessary work to ensure they can be licensed and released for sale in mainland Europe has not yet been carried out. The assessment has come from the European Medicines Agency, the regulator, following a survey of action taken by pharmaceutical companies to safeguard supplies of almost 700 products whose marketing authorisations were granted in the UK. In order to ensure that the medicines can continue to be available throughout Europe once Britain leaves the EU, this authorisation may need to be “transferred to a legal entity established in the European Economic Area”, said the EMA.
Mon, 02 Jul 2018
11:25:00 +0000
Complimentary Technical Snapshots on Mylan and Three More Generic Drugs Stocks
Ahead of today's trading session, WallStEquities.com assesses Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). The biggest catalyst of the Generic Drugs industry is the significantly lower price of generics compared to branded drugs.
Thu, 28 Jun 2018
21:31:09 +0000
Medicines Company's Inclisiran Studies to Continue Unmodified
The Medicines Company (MDCO) announces that Independent Data Monitoring Committee has recommended that the ongoing phase III studies of its candidate, inclisiran, will continue without modification.
Wed, 27 Jun 2018
11:00:00 +0000
The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following Review of Unblinded Data
The Medicines Company (MDCO) today announced that the Independent Data Monitoring Committee (IDMC) for the ongoing inclisiran Phase III trials has recommended that the trials continue as designed and conducted, without modification. The IDMC’s recommendation was based on its planned review of unblinded safety and efficacy data from the trials. The ORION Phase III studies with 18-months follow up were fully enrolled between November 2017 and March 2018, with 3,660 patients randomized 1:1 across three trials – ORION-9 (482 patients randomized), ORION-10 (1,561 patients randomized) and ORION-11 (1,617 patients randomized) – to receive either inclisiran or placebo.
Tue, 26 Jun 2018
11:00:00 +0000
New Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce the Potential of The Medicines Company’s inclisiran in Patients with Diabetes
The Medicines Company (MDCO) today announced the presentation of new data from a pre-specified, sub-group analysis of dosing, efficacy and safety of inclisiran in patients with diabetes from the ORION-1 Phase II trial at the American Diabetes Association (ADA) 78th Scientific Sessions® in Orlando (ADA 2018). Professor Lawrence Leiter, Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto, reported the data during an oral presentation at ADA 2018. The data showed that a subcutaneous injection of 300 mg of inclisiran given at Day-1 and Day-90 lowered LDL-cholesterol (LDL-C) at Day-180 by more than 50% in patients with atherosclerotic cardiovascular disease (ASCVD) and those considered ASCVD-risk equivalents, regardless of whether those patients had diabetes.
Mon, 11 Jun 2018
20:49:08 +0000
Alnylam Reports Positive Data on Lumasiran in Renal Disease
Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients.
Fri, 08 Jun 2018
00:50:39 +0000
What Does The Medicines Company’s (NASDAQ:MDCO) Share Price Indicate?
The Medicines Company (NASDAQ:MDCO), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGS over the last few months. AsRead More...
Tue, 29 May 2018
12:30:00 +0000
Today's Research Reports on Trending Tickers: Horizon Pharma and The Medicines Company
NEW YORK, NY / ACCESSWIRE / May 29, 2018 / OPEC and major oil-producer Russia were considering an increase in supply, pressuring energy stocks lower. U.S. markets however posted weekly gains on Friday, ...
Fri, 25 May 2018
13:11:01 +0000
Medicines Company (MDCO) Up 11.4% Since Earnings Report: Can It Continue?
Medicines Company (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Thu, 24 May 2018
11:15:00 +0000
Free Daily Technical Summary Reports on Mylan and Three Other Generic Drugs Stocks
Pre-market, WallStEquities.com takes a look at the recent performance of Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). On Wednesday, shares in Canonsburg, Pennsylvania headquartered Mylan N.V. recorded a trading volume of 3.81 million shares.
Mon, 07 May 2018
14:45:00 +0000
The Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of Bad Cholesterol (Atherogenic Lipoproteins) Linked to Heart Attack and Stroke
The Medicines Company (MDCO) today announced that the results of a pre-specified analysis of secondary endpoints from the ORION-1 Phase II study were presented at the 86th European Atherosclerosis Society Congress (EAS 2018) and accepted for publication in Circulation, the journal of the American Heart Association. Investigators examined inclisiran’s effects beyond LDL-C and showed that it also reduces atherogenic lipoproteins in a profound and sustained manner. Atherogenic lipoproteins – non-HDL-C, ApoB, VLDL-C and Lp(a) – have each been associated with an increased risk of heart attacks and strokes, particularly in high-risk patients.
Thu, 03 May 2018
11:50:00 +0000
Blog Exposure - Ironwood to Separate Its Soluble Guanylate Cyclase Business from Commercial and Gastrointestinal Business
LONDON, UK / ACCESSWIRE / May 03, 2018 / Active-Investors.com has just released a free research report on Ironwood Pharma, Inc. (IRWD). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=IRWD as the Company's latest news hit the wire. On May 01, 2018, the Company declared that its Board of Directors has approved an intent to separate into two independent, publicly-traded Companies, i.e.
Mon, 30 Apr 2018
11:00:00 +0000
The Medicines Company Presents New Data at the National Lipid Association Scientific Sessions
The Medicines Company presented important new data and analyses from the ORION development program for inclisiran at the National Lipid Association 2018 Scientific Sessions held in Las Vegas, NV.
Fri, 27 Apr 2018
16:19:04 +0000
Medicines Company's (MDCO) Q1 Loss Widens, Revenues Tank Y/Y
The Medicines Company (MDCO) incurs wider-than-expected loss in the first quarter of 2018. The top line also missed estimates and declined year over year.
Thu, 26 Apr 2018
04:15:10 +0000
Edited Transcript of MDCO earnings conference call or presentation 25-Apr-18 12:30pm GMT
Q1 2018 Medicines Co Earnings Call
Wed, 25 Apr 2018
11:16:21 +0000
Medicines Co.: 1Q Earnings Snapshot
The Parsippany, New Jersey-based company said it had net income of 39 cents per share. Losses, adjusted for one-time gains and costs, came to 76 cents per share. The results did not meet Wall Street expectations. ...
Wed, 25 Apr 2018
11:00:00 +0000
The Medicines Company Reports First-Quarter 2018 Results
The Medicines Company today reported its financial results for the first quarter ended March 31, 2018.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "There is power in numbers. It's obvious that most brokers don't have a clue of what they recommend to clients. Rarely do they own what they are talking about. Here at VF it's real. Real people with real positions giving their takes on the good w/ the bad. "Knowledge always beats strength" is a great quote. Here, at VF, I hope to see the sharing of knowledge become our strength." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards